Marked amelioration of alcohol‐responsive posthypoxic myoclonus by γ‐hydroxybutyric acid (Xyrem)
Identifieur interne : 003854 ( Main/Exploration ); précédent : 003853; suivant : 003855Marked amelioration of alcohol‐responsive posthypoxic myoclonus by γ‐hydroxybutyric acid (Xyrem)
Auteurs : Steven J. Frucht [États-Unis] ; Yvette Bordelon [États-Unis] ; William H. Houghton [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-06.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Alcool.
English descriptors
- KwdEn :
- Adult, Alcohol, Central Nervous System Depressants (administration & dosage), Dose-Response Relationship, Drug, Ethanol (administration & dosage), Evaluation scale, Female, Humans, Hydroxybutyrates (therapeutic use), Hypoxia, Myoclonus, Myoclonus (drug therapy), Nervous system diseases, Neurologic Examination, Psychomotor Performance (drug effects), Severity of Illness Index, Sodium oxybate, Treatment Outcome, Xyrem, gamma‐hydroxybutyric acid, hypoxia, myoclonus, rating scale.
- MESH :
- chemical , administration & dosage : Central Nervous System Depressants, Ethanol.
- chemical , therapeutic use : Hydroxybutyrates.
- drug effects : Psychomotor Performance.
- drug therapy : Myoclonus.
- Adult, Dose-Response Relationship, Drug, Female, Humans, Neurologic Examination, Severity of Illness Index, Treatment Outcome.
Abstract
We conducted an open‐label, dose‐finding, blinded‐rating trial of γ‐hydroxybutyric acid (Xyrem) in a single patient with severe alcohol‐responsive posthypoxic myoclonus refractory to treatment with standard antimyoclonic agents. Xyrem was given in divided doses during the day and was well tolerated. Intensity of myoclonus was measured using the Unified Myoclonus Rating Scale, and blinded videotape review demonstrated complete resolution of myoclonus at rest and stimulus‐sensitive myoclonus. Action myoclonus and functional performance also improved in ways that were practically meaningful, allowing her to feed herself, to accomplish daily hygiene tasks, and to walk with assistance. The possible mechanisms of action and potential uses of this agent in other alcohol‐responsive movement disorders are discussed. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20452
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002008
- to stream Istex, to step Curation: 002008
- to stream Istex, to step Checkpoint: 002262
- to stream PubMed, to step Corpus: 003105
- to stream PubMed, to step Curation: 003105
- to stream PubMed, to step Checkpoint: 003067
- to stream Ncbi, to step Merge: 001196
- to stream Ncbi, to step Curation: 001196
- to stream Ncbi, to step Checkpoint: 001196
- to stream Main, to step Merge: 004F39
- to stream PascalFrancis, to step Corpus: 001E52
- to stream PascalFrancis, to step Curation: 000E69
- to stream PascalFrancis, to step Checkpoint: 001D99
- to stream Main, to step Merge: 005277
- to stream Main, to step Curation: 003854
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Marked amelioration of alcohol‐responsive posthypoxic myoclonus by γ‐hydroxybutyric acid (Xyrem)</title><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name></author><author><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name></author><author><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H." last="Houghton">William H. Houghton</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F3F038259FE242A6E85C20C973E035BE064FA4B0</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20452</idno><idno type="url">https://api.istex.fr/document/F3F038259FE242A6E85C20C973E035BE064FA4B0/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002008</idno><idno type="wicri:Area/Istex/Curation">002008</idno><idno type="wicri:Area/Istex/Checkpoint">002262</idno><idno type="wicri:doubleKey">0885-3185:2005:Frucht S:marked:amelioration:of</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15751049</idno><idno type="wicri:Area/PubMed/Corpus">003105</idno><idno type="wicri:Area/PubMed/Curation">003105</idno><idno type="wicri:Area/PubMed/Checkpoint">003067</idno><idno type="wicri:Area/Ncbi/Merge">001196</idno><idno type="wicri:Area/Ncbi/Curation">001196</idno><idno type="wicri:Area/Ncbi/Checkpoint">001196</idno><idno type="wicri:doubleKey">0885-3185:2005:Frucht S:marked:amelioration:of</idno><idno type="wicri:Area/Main/Merge">004F39</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:05-0363486</idno><idno type="wicri:Area/PascalFrancis/Corpus">001E52</idno><idno type="wicri:Area/PascalFrancis/Curation">000E69</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001D99</idno><idno type="wicri:doubleKey">0885-3185:2005:Frucht S:marked:amelioration:of</idno><idno type="wicri:Area/Main/Merge">005277</idno><idno type="wicri:Area/Main/Curation">003854</idno><idno type="wicri:Area/Main/Exploration">003854</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Marked amelioration of alcohol‐responsive posthypoxic myoclonus by γ‐hydroxybutyric acid (Xyrem)</title><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Columbia University Medical Center; New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Columbia University Medical Center; New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H." last="Houghton">William H. Houghton</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Orphan Medical, Inc., Minnetonka, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-06">2005-06</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="745">745</biblScope><biblScope unit="page" to="751">751</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F3F038259FE242A6E85C20C973E035BE064FA4B0</idno><idno type="DOI">10.1002/mds.20452</idno><idno type="ArticleID">MDS20452</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Alcohol</term><term>Central Nervous System Depressants (administration & dosage)</term><term>Dose-Response Relationship, Drug</term><term>Ethanol (administration & dosage)</term><term>Evaluation scale</term><term>Female</term><term>Humans</term><term>Hydroxybutyrates (therapeutic use)</term><term>Hypoxia</term><term>Myoclonus</term><term>Myoclonus (drug therapy)</term><term>Nervous system diseases</term><term>Neurologic Examination</term><term>Psychomotor Performance (drug effects)</term><term>Severity of Illness Index</term><term>Sodium oxybate</term><term>Treatment Outcome</term><term>Xyrem</term><term>gamma‐hydroxybutyric acid</term><term>hypoxia</term><term>myoclonus</term><term>rating scale</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Central Nervous System Depressants</term><term>Ethanol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Hydroxybutyrates</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Psychomotor Performance</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Myoclonus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Neurologic Examination</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Alcool</term><term>Echelle d'évaluation</term><term>Hypoxie</term><term>Myoclonie</term><term>Oxybate sodium</term><term>Système nerveux pathologie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Alcool</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We conducted an open‐label, dose‐finding, blinded‐rating trial of γ‐hydroxybutyric acid (Xyrem) in a single patient with severe alcohol‐responsive posthypoxic myoclonus refractory to treatment with standard antimyoclonic agents. Xyrem was given in divided doses during the day and was well tolerated. Intensity of myoclonus was measured using the Unified Myoclonus Rating Scale, and blinded videotape review demonstrated complete resolution of myoclonus at rest and stimulus‐sensitive myoclonus. Action myoclonus and functional performance also improved in ways that were practically meaningful, allowing her to feed herself, to accomplish daily hygiene tasks, and to walk with assistance. The possible mechanisms of action and potential uses of this agent in other alcohol‐responsive movement disorders are discussed. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Minnesota</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name></region><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H." last="Houghton">William H. Houghton</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003854 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003854 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F3F038259FE242A6E85C20C973E035BE064FA4B0
|texte= Marked amelioration of alcohol‐responsive posthypoxic myoclonus by γ‐hydroxybutyric acid (Xyrem)
}}
| This area was generated with Dilib version V0.6.23. |  |